Adaptive Biotechnologies (ADPT) Cash & Current Investments (2018 - 2026)

Adaptive Biotechnologies (ADPT) has 9 years of Cash & Current Investments data on file, last reported at $218.3 million in Q1 2026.

• Quarterly Cash & Current Investments rose 12.88% year-over-year to $218.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $218.3 million (up 12.88% YoY) and the FY2025 annual result came in at $227.0 million, up 2.11% from the prior year.
• Cash & Current Investments declined to $218.3 million in Q1 2026 per ADPT's latest filing, from $227.0 million in the prior quarter.
• The five-year high for Cash & Current Investments was $508.1 million in Q3 2022, with the low at $193.4 million in Q1 2025.
• Average Cash & Current Investments over 5 years is $320.3 million, with a median of $308.9 million recorded in 2024.
• The widest YoY moves for Cash & Current Investments: up 41.11% in 2022, down 49.1% in 2022.
• Adaptive Biotechnologies' Cash & Current Investments stood at $498.2 million in 2022, then plunged by 30.47% to $346.4 million in 2023, then tumbled by 35.83% to $222.3 million in 2024, then advanced by 2.11% to $227.0 million in 2025, then fell by 3.81% to $218.3 million in 2026.
• Business Quant data shows ADPT's Cash & Current Investments at $218.3 million in Q1 2026, $227.0 million in Q4 2025, and $212.8 million in Q3 2025.